Table 1.

Baseline characteristics of the study population in primary and recurrent samples.

Variable		Total (N = 122)	Primary (N = 61)	Recurrent (N = 61)	p-Value
Age (y)	≤60	77 (63.1)	41 (67.2)	36 (59)	0.45
	>60	45 (36.9)	20 (32.8)	25 (41)
Sex	Male	82 (67.2)	42 (68.9)	40 (65.6)	0.85
	Female	40 (32.8)	19 (31.1)	21 (34.4)
Location	Right	67 (54.9)	35 (57.4)	32 (52.5)	0.49
	Transverse	7 (5.7)	2 (3.3)	5 (8.2)
	Left	48 (39.3)	24 (39.3)	24 (39.3)
Type	Adenocarcinoma	84 (68.9)	41 (67.2)	43 (70.5)	0.75
	Mucinous	16 (13.1)	7 (11.5)	9 (14.8)
	Signet cell	18 (14.8)	11 (18)	7 (11.5)
	Undifferentiated	4 (3.3)	2 (3.3)	2 (3.3)
Grade	G1/2	83 (68)	41 (67.2)	42 (68.9)	0.84
	G3	39 (32)	20 (32.8)	19 (31.1)
T stage	T1/2	65 (53.3)	32 (52.5)	33 (54.1)	0.85
	T3/4	57 (46.7)	29 (47.5)	28 (45.9)
N stage	N0	45 (36.9)	20 (32.8)	25 (41)	0.45
	N1	77 (63.1)	41 (67.2)	36 (59)
M stage	M0	98 (80.3)	49 (80.3)	49 (80.3)	0.82
	M1	24 (19.7)	12 (19.7)	12 (19.7)
Lymphovascular invasion	No	82 (67.2)	41 (67.2)	41 (67.2)	0.85
	Yes	40 (32.8)	20 (32.8)	20 (32.8)
Duke’s stage	A/B	63 (51.6)	31 (50.8)	32 (52.5)	0.85
	C/D	59 (48.4)	30 (49.2)	29 (47.5)
BRAF mutation	Wild type	86 (70.5)	42 (68.9)	44 (72.1)	0.84
	Mutant	36 (29.5)	19 (31.1)	17 (27.9)
Relapse	No	83 (68)	44 (72.1)	39 (63.9)	0.43
	Yes	39 (32)	17 (27.9)	22 (36.1)
Mortality	Survived	90 (73.8)	49 (80.3)	41 (67.2)	0.15
	Died	32 (26.2)	12 (19.7)	20 (32.8)
Disease-free survival	Prolonged > 2y	46 (39)	21 (36.2)	25 (41.7)	0.57
	Short ≤ 2y	72 (61)	37 (63.8)	35 (58.3)
Overall survival	Prolonged > 2y	61 (52.6)	30 (51.7)	31 (53.4)	0.85
	Short ≤ 2y	55 (47.4)	28 (48.3)	27 (46.6)

Data are presented as frequency (percentage). A two sided-Chi-square test was used. Statistical significance was set at a p-value below 0.05.